Clinical trials: Geriatric Cancer Patients
Acute Myelogenous Leukemia
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
The goal of Part 1 of this clinical research study is to learn about the safety of the combination of plerixafor and clofarabine when given to patients with previously untreated AML who are at least 60 years old.
- Trial name
- NCT01160354
- Testing
- Plerixafor, Clofarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Remote Monitoring for Ambulatory Care of Elderly Patients With Cancer
Monocentric, prospective cohort pilot study evaluating the feasibility of a online remote monitoring tool during the care of patients over 65 years of age being medically treated for cancer.
- Trial name
- TS-PAC (NCT04913259)
- Testing
- Remote monitoring
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Bergonié
Acute Myeloid Leukemia
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
The objective is to treat elderly AML and MDS patients with sapacitabine.
- Trial name
- NCT00590187
- Testing
- Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C
- Where
- 15 sites in United States
- Volunteers
- 105 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of…
- Trial name
- NCT04914676
- Testing
- Cytarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Florida
Breast Cancer
Single Fraction Elderly Breast Irradiation (SiFEBI)
Irradiation and Accelerated Partial Breast (IPAS) to this day remains a therapeutic concept whose validity is being assessed on its non-inferiority in terms of local control compared to whole breast irradiation.
- Trial name
- SIFEBI (NCT01727011)
- Testing
- IPAS
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Antoine Lacassagne
Non-Small Cell Lung Cancer
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
The primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIB/IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT00517595
- Testing
- Pemetrexed and Gemcitabine plus Bevacizumab
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Acute Myeloid Leukemia
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens.
- Trial name
- NCT00788892
- Testing
- CPX-351, Cytarabine, Daunorubicin
- Where
- 28 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years…
- Trial name
- NCT00513305
- Testing
- Arsenic trioxide, Low-dose cytarabine alone
- Where
- 12 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Cephalon
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT01077713
- Testing
- bevacizumab [Avastin], cisplatin, gemcitabine
- Where
- 26 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Non Small Cell Lung Cancer
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
- Trial name
- NCT00350792
- Testing
- pemetrexed, carboplatin
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Digestive System Diseases
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated.
- Conditions
- Lymphoma, Digestive System Diseases, Ovarian Diseases, Pulmonary Disease
- Trial name
- PHRC2003 (NCT00210249)
- Where
- 18 sites in France
- Volunteers
- 364 people
- Sponsor
- Institut Bergonié
Carcinoma, Non-Small-Cell Lung
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
- Trial name
- NSCLC (NCT00553800)
- Testing
- bevacizumab, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Rectal Neoplasms
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
This phase I study is designed to determine the maximum tolerant dose of capecitabine when used in preoperative concurrent chemo-radiation for locally advanced rectal patients over 75 years old.
- Trial name
- NCT01584544
- Testing
- capecitabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese Academy of Medical Sciences
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Non-small Cell Lung Cancer
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
- Trial name
- 6137p (NCT01011075)
- Testing
- Imatinib mesylate, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- New Mexico Cancer Research Alliance
Pancreatic Metastatic Cancer, Toxicity
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
Metastatic pancreatic carcinomas represent the 5th cause of cancer death in France (#8000 per year). The median age at diagnosis is 69 and 74 in male and female respectively.
- Trial name
- PAMELA70 (NCT02143219)
- Testing
- Oxaliplatine, Folinic acid, Irinotecan
- Where
- 6 sites in France
- Volunteers
- 72 people
- Sponsor
- Institut Cancerologie de l'Ouest